Dragonfly Therapeutics - Dragonfly Therapeutics是一家临床阶段的生物技术公司，致力于发现、开发和商业化利用人体免疫系统的新疗法，为患者带来突破性治疗方案[5] - Dragonfly的平台技术已经有第八种药物进入临床试验，其中第六种TriNKET®正在进行临床试验[1] AbbVie - AbbVie（NYSE: ABBV）对ABBV-303进行了临床试验，这是第一种由AbbVie授权的TriNKET®药物候选进入临床试验[3] - AbbVie已经将ABBV-303推进到临床试验阶段，这是对患有复杂疾病的患者提供潜在新治疗选择的重要进展[4]

Investing in dividend kings is about keeping things simple. A distinguishing feature of these companies is a rock-solid balance sheet that allows them to demonstrate unwavering commitment to building shareholder value. In fact, to become a dividend king a company must increase their dividend for at least 50 consecutive years.  You won’t find these companies on any “Magnificent 7” list of tech stocks. They aren’t going to be leading the AI revolution or renewable energy transformation. However, what dividend ...

公司表现 - AbbVie (ABBV) 最新收盘价为178.91美元，较上一交易日上涨1.62%[1] - 过去一个月，该药企股价上涨了5.05%，超过了医疗行业的3.58%增幅[2] - AbbVie目前的Forward P/E比率为15.79，高于行业平均值14.9，显示公司的股价溢价[7] 分析师预测 - 分析师预计AbbVie即将发布的每股收益为2.34美元，较去年同期下降了4.88%；预计营收为119.4亿美元，较去年同期下降了2.31%[3] - Zacks Consensus Estimates预测AbbVie全年每股收益为11.15美元，营收为545亿美元，较去年分别增长了0.36%和0.33%[4] - 投资者应关注分析师对AbbVie的最新预测变化，积极的变化代表分析师对公司业务和盈利能力的乐观态度[5] 行业比较 - ABBV的PEG比率为2.24，高于昨日收盘价的Large Cap Pharmaceuticals行业平均值1.67[8] - Large Cap Pharmaceuticals行业属于医疗行业，行业排名为177，属于所有250+行业中的后30%[9] - Zacks Industry Rank通过测量组内个股的平均Zacks Rank来评估行业群体的实力，研究显示排名前50%的行业胜过后50%的行业[10] 建议 - 研究表明，预测变化与未来股价表现直接相关，公司开发了Zacks Rank模型，考虑这些预测变化并提供可操作的评级系统[6] - 使用Zacks.com监控所有这些影响股价的指标，并在未来交易中持续关注[11]

It’s often said that patience is a virtue for investors that often means taking advantage of the stability of blue-chip stocks.  However, that virtue can be sorely lacking among investors. In good times, investors are frequently drawn to the next shiny object. And when growth is hard to come by, they can move into more speculative assets, seeking growth at all costs. But history says investors with a long-term focus can still do better looking at solid blue-chip stocks. These stocks frequently are in defens ...

Since the beginning of the 20th century, dividend stocks have accounted for 75% of the total returns in the U.S. stock market. Dividend growth stocks, which are companies that regularly increase their cash payouts to shareholders annually, have significantly outperformed the majority of other asset classes over this 124-year span.The primary reason for this is the power of compounding. By owning a dividend growth stock and reinvesting the dividends each quarter, your investment can experience exponential gr ...

-   Global license and collaboration agreement to focus on the development of OSE-230, a monoclonal antibody designed to resolve chronic inflammation -   OSE Immunotherapeutics to receive an upfront payment of $48 million and will be eligible to receive up to an additional $665 million in milestone payments NORTH CHICAGO, Ill. and NANTES, France, Feb. 28, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, toda ...

epcoritamab-bysp - AbbVie宣布美国FDA已对epcoritamab-bysp的补充生物制品许可申请进行了优先审查[1] - epcoritamab-bysp将成为首个用于治疗成人R/R FL的皮下双特异性抗体，标志着其第二个适应症[1] - epcoritamab是AbbVie和Genmab共同开发的，旨在成为核心淋巴瘤治疗药物[3] - EPCORE™ NHL-1试验评估了epcoritamab在治疗复发性或难治性FL患者中的疗效和安全性[5] - epcoritamab已在全球获得批准用于治疗特定类型的大B细胞淋巴瘤，但在FL患者中的使用尚未获得批准[7] - Genmab和AbbVie正在评估epcoritamab在不同治疗方案中的使用，包括作为单药疗法和联合疗法[8] 患者治疗 - 美国患有弥漫性大B细胞淋巴瘤和滤泡性淋巴瘤的患者的经济负担和治疗模式[32] - 滤泡性淋巴瘤患者在利妥昔单抗时代的每次复发后，反应持续时间和生存时间缩短[34] 新疗法研究 - DuoBody-CD3xCD20在临床模型中诱导恶性B细胞的强效T细胞介导杀伤，并提供皮下给药的机会[35]

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. The FDA grants Priority Review to investigational ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. ("Cosette") announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for the first generic version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity. Cosette will imminently commence commercial shipments, triggering the 180 days exclusivity. Apurva Saraf, President and CEO of Cosette Pharma, stated, "This is a pivotal product appr ...

Collaboration to leverage AbbVie's therapeutic area expertise and Tentarix's Tentacles™ platform, to develop novel multifunctional biologics against one target in oncology and another in immunology AbbVie will receive an exclusive option to acquire the therapeutic programs following candidate nomination by Tentarix NORTH CHICAGO, Ill. and SAN DIEGO, Feb. 22, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and de ...